TYROSIN-KINASE-INHIBITOREN

Patent europeic · EP3912979 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3912979
Numer da la dumonda
EP21169631
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
02-06-2016
Publitgà
24-11-2021
Concedì
25-03-2026
La protecziun finescha il pli tard
01-06-2036
Proxima taxa annuala scadenta
30-06-2027
Classas IPC
C07D 471/04 (2006.01)
C07D 473/34 (2006.01)
A61K 31/437 (2006.01)
A61K 31/52 (2006.01)
A61P 35/00 (2006.01)
A61P 37/00 (2006.01)
Prioritad
US 201562170547 P 03.06.2015
US 201562271689 P 28.12.2015
Derivà da
EP16728566
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-07-2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. 25-03-2026

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 25.03.2026

Partidas

Possessur

Principia Biopharma Inc.

100 Morris St., Morristown, NJ 07960, US

Inventur

GOLDSTEIN, David

Redwood City, 94061, US

OWENS, Timothy D.

Redwood City, 94061, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.